Ortho-K vs. Atropine vs. Multifocal: Comparing Options for Myopia Control
Myopia management has three primary clinical pathways: orthokeratology (Ortho-K), atropine eye drops, and multifocal contact lenses. Each approach slows the progression of nearsightedness through a different mechanism, and the right fit depends on your child's age, lifestyle, and how fast their prescription is changing.
Key Takeaways
Ortho-K reshapes the cornea overnight, giving daytime freedom without glasses or contacts, and represents the fastest-growing segment in the myopia management market.
Low-dose atropine drops are simple to use but carry a rebound risk when discontinued; 0.05% concentration reduces myopia incidence by nearly 50% according to Clinical Optometry, 2025.
Multifocal contact lenses are worn during the day and offer a comfortable option for children who are not good candidates for overnight lenses.
Combination therapy, such as Ortho-K paired with atropine, is perceived by practitioners as the most effective approach for myopia control (Review of Myopia Management, 2024).
Cost, compliance, and the risk of stopping treatment early are practical factors that often determine which option actually works long-term.
A specialist consultation, such as those offered at Texas Contact Lens Institute in Plano, TX, is the most reliable way to match treatment to your child's specific clinical profile.
Ortho-K: Corneal Reshaping That Works While Your Child Sleeps
Orthokeratology uses specially designed rigid gas-permeable lenses worn overnight. While your child sleeps, the lenses gently reshape the front surface of the cornea. By morning, the lenses come out and clear, unaided vision remains for most of the day. No glasses, no daytime contacts.
From a myopia control standpoint, Ortho-K does more than correct vision. The reshaped cornea creates peripheral defocus, a signal that appears to slow axial elongation, which is the core mechanism driving myopia progression. According to a one-year comparative study of 282 children published in Contact Lens and Anterior Eye (2024), Ortho-K delayed axial elongation by 41.03% compared to spectacle wearers, with 69.0% of Ortho-K patients experiencing 0.3 mm or less of elongation over the study period.
Orthokeratology lenses represent the fastest-growing segment in the global myopia management market, which reached $2.61 billion in 2024 and is projected to hit $9.13 billion by 2033 at a 15.9% CAGR, according to Growth Market Reports (2024).
Key considerations for Ortho-K:
Best suited for children ages 8 and older who can handle lens insertion and removal
Requires nightly wear consistency; skipping nights reduces daytime clarity
Not ideal for children in contact sports where overnight routines are disrupted
Higher upfront cost than atropine drops; typically ranges from $1,000 to $2,000 per year depending on your provider and location
Regular follow-up visits are necessary to monitor corneal health
For more on how corneal reshaping affects the eye structurally, the Dovepress research on orthokeratology's corneal impact offers peer-reviewed detail.
Soft Multifocal Contact Lenses: Daytime Myopia Control Without the Overnight Commitment
Soft multifocal lenses, such as MiSight 1 day by CooperVision, are worn during waking hours and removed at night. They work similarly to Ortho-K in that they create peripheral defocus to slow axial elongation, but they do so with a soft lens that many children find more comfortable from day one.
MiSight is currently the only FDA-approved soft contact lens for myopia control in the United States, making it a clinically credible option. A clinical trial comparing atropine and MiSight is actively recruiting as of 2024, underscoring the growing interest in head-to-head efficacy data.
Key considerations for soft multifocals:
Daily disposable versions eliminate lens care routines, reducing infection risk
Easier transition for children who are already accustomed to soft lenses
Requires consistent daytime wear; forgetting lenses at home means no myopia control for that day
Annual cost is comparable to Ortho-K, often $1,200 to $1,800 depending on lens brand and fitting fees
Not suitable for children with certain corneal irregularities or very high prescriptions
Multifocal lenses are a strong middle-ground option for children whose families prefer not to manage overnight lenses or who have concerns about corneal reshaping at a young age.
Atropine Drops: Pharmaceutical Myopia Control With a Daily Routine
Atropine is a medication that, in low concentrations, appears to slow the biological signals that drive axial elongation. Unlike Ortho-K or multifocals, it does not correct vision on its own. It is used alongside standard glasses or contact lenses as an add-on therapy.
Concentration matters significantly. According to Clinical Optometry (2025), 0.05% atropine reduces myopia incidence by nearly 50%, though this concentration comes with a higher risk of rebound progression if the drops are discontinued abruptly. Lower concentrations, such as 0.01%, have fewer side effects but provide more modest control in some children.
The MOSAIC trial published in JAMA Ophthalmology (2025) evaluated the efficacy and safety of different atropine regimens over three years, reinforcing the importance of concentration selection and supervised tapering when stopping treatment.
The childhood atropine market was estimated at $1.1 billion in 2024 and is projected to reach $2.8 billion by 2034, according to Exactitude Consultancy (2024).
Known side effects of atropine:
Light sensitivity and glare, more pronounced at higher concentrations
Temporary blurred near vision, particularly at 0.05% and above
Rebound myopia progression after discontinuation if not tapered carefully
Requires prescription from a licensed provider; not available over the counter
Cost note: Low-dose atropine is often compounded by a specialty pharmacy and is not widely covered by insurance in the US. Monthly costs typically range from $30 to $150 depending on concentration and pharmacy.
Combination Therapy: When One Approach Is Not Enough
One of the most significant developments in recent myopia research is the evidence supporting combination treatment. According to a study published in Eye (2024), the combination of Ortho-K and 0.01% atropine achieved the best myopia control efficacy over a one-year follow-up period.
Research published in Scientific Reports (2025) found that sequentially adding atropine at concentrations of 0.01%, 0.025%, and 0.05% to an existing Ortho-K regimen reduced annual axial elongation by 28.4%, 31.4%, and 39.4%, respectively. These figures suggest a meaningful dose-response relationship when combining therapies.
For more clinical context on combination approaches and current best practices, Optometry Times covers the latest in myopia control with updated practitioner insights.
Combination therapy tends to be recommended when:
A child is progressing rapidly despite single-modality treatment
Axial length measurements show continued elongation after six months
The child is approaching an age at which the risk of high myopia complications increases
Choosing the Right Option Based on Age, Lifestyle, and Risk
No single treatment is universally best. The decision framework your eye doctor uses typically weighs several factors.
According to a global practitioner survey reported by the Review of Myopia Management (2024), combination treatment was perceived as the most effective approach overall, followed by orthokeratology and pharmaceutical methods.
The NIH's National Eye Institute provides background on myopia as a growing public health concern, which underscores why early intervention matters regardless of which method you choose.
Things to Know
Ortho-K is not FDA-approved specifically for myopia control in the US, but the lenses themselves are FDA-cleared, and off-label use for control is well-documented.
Atropine drops must be tapered gradually under clinical supervision; stopping suddenly can trigger faster-than-normal progression.
Insurance rarely covers myopia management treatments in the US; flexible spending accounts (FSAs) can often offset costs.
Axial length measurement (not just prescription change) is the gold-standard metric for evaluating whether any treatment is working.
Compliance is the biggest real-world predictor of outcomes; the best treatment is the one your child will actually use consistently.
Frequently Asked Questions
Q: At what age should myopia management treatment start?
Earlier is generally better, since younger eyes tend to progress faster.
Most eye doctors recommend beginning myopia management as soon as progression is documented, which often occurs between ages 6 and 12. The specific treatment choice depends on the child's maturity and ability to comply with the routine.
Q: Can Ortho-K and atropine be used at the same time?
Yes, and research supports the combination as more effective than either therapy alone.
A study in Eye (2024) found that Ortho-K combined with 0.01% atropine delivered the best one-year myopia control outcomes. This approach is typically considered when a child is still progressing despite one treatment.
Q: What happens if my child stops wearing Ortho-K lenses?
The cornea gradually returns to its original shape, usually within one to two weeks, and myopia resumes.
Unlike atropine, there is no significant rebound effect beyond the return of the original prescription. Many families plan for this transition when a child is old enough for LASIK eligibility.
Q: Are multifocal contact lenses safe for young children?
Yes, with proper fitting and supervision they are considered safe for children as young as six.
Studies supporting MiSight use in children as young as eight are well-documented, and the lens's daily disposable format reduces infection risk compared to reusable lenses.
Q: Does insurance cover any of these myopia management treatments in the US?
Most standard vision insurance plans do not cover myopia control treatments as a distinct benefit.
Some medical insurance policies may cover atropine if prescribed for a documented medical indication, but coverage is inconsistent. It is worth calling your insurer and asking specifically about myopia management or axial elongation treatment codes.
The Bottom Line on Ortho-K vs. Atropine vs. Multifocal: Comparing Options
Each treatment addresses myopia progression through a different mechanism, at a different price point, and with a different daily routine. Ortho-K suits children who want daytime freedom and can handle an overnight lens routine. Soft multifocals work well for children who prefer daytime wear and a familiar lens feel. Atropine is the simplest to administer but requires careful management of concentration and discontinuation. For children who are progressing despite one treatment, combination therapy is increasingly supported by the clinical literature.
If your child's prescription has been changing year over year and you want a structured, evidence-based plan, the team at Texas Contact Lens Institute in Plano, TX is a strong starting point. Call them at +1 972-299-8675 or visit their office at 6020 W Parker Rd, Suite 260, Plano, TX 75093 to schedule a myopia management consultation and get a recommendation tailored to your child's current axial length and lifestyle.
